18 Leukemia Clinical Trials in Durham, NC (2026)

Q: Are there leukemia clinical trials in Durham?

Yes, there are 18 leukemia clinical trials currently recruiting in Durham, NC.

Q: How do I join a clinical trial in Durham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you.

Q: Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatments, medical tests, and doctor visits are provided at no cost.

Recruiting Leukemia Studies in Durham

NCT06040541Recruiting

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors....

Durham, NCPHASE1604 participantsRevolution Medicines, Inc.

View Study Details

NCT06646276Recruiting

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab...

Durham, NCPHASE3530 participantsBristol-Myers Squibb

View Study Details

NCT07325136Recruiting

A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer

The purpose of this study is to assess the safety and tolerability of BMS-986525 alone and in combination with Nivolumab in participants with Relapsed/Refractory Small Cell Lung Cancer...

Durham, NCPHASE1240 participantsBristol-Myers Squibb

View Study Details

NCT06802406Recruiting

Nutrition OUtReach In Systems of Healthcare

Many children and adults receiving medical treatments have higher costs, which can make it harder for them to afford groceries. When someone can't afford enough food, and they do not receive proper nu...

Durham, NCNA210 participantsUniversity of Kansas Medical Center

View Study Details

NCT03481881Recruiting

Pharmacokinetics of Drugs Administered to Children

This is a prospective study of children \<21 years of age with the goal of characterizing the PK of drugs administered per standard of care as prescribed by the treating caregiver....

Durham, NC200 participantsDuke University

View Study Details

NCT06472128Recruiting

Novel Digital Application for Patients With Acute Leukemia

This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes fo...

Durham, NCNA200 participantsMassachusetts General Hospital

View Study Details

NCT07246863Recruiting

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivoluma...

Durham, NCPHASE2131 participantsCatalYm GmbH

View Study Details

NCT05362773Recruiting

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

CP-MGD024-01 is a Phase 1, open-label, multi-center study of MGD024 as a single agent in participants with select blood cancers that have not responded to treatment with standard therapies or who have...

Durham, NCPHASE1130 participantsMacroGenics

View Study Details

NCT07098988Recruiting

Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC

This is an exploratory, signal finding, randomized, placebo-controlled, blinded, multi-center Phase 2b trial of the anti GDF-15 antibody Visugromab (CTL-002) versus Placebo, combined with Immunochemot...

Durham, NCPHASE2107 participantsCatalYm GmbH

View Study Details

NCT06520098Recruiting

A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This t...

Durham, NCPHASE2100 participantsVA Office of Research and Development

View Study Details

NCT07221500Recruiting

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent...

Durham, NCPHASE2100 participantsNurix Therapeutics, Inc.

View Study Details

NCT07155226Recruiting

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with ...

Durham, NCPHASE184 participantsAstraZeneca

View Study Details

NCT07024706Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

This study will evaluate the efficacy and safety of finite-duration acalabrutinib plus venetoclax therapy in patients with relapsed CLL or SLL, and have previously responded to first line (1L) cBTKi +...

Durham, NCPHASE280 participantsAstraZeneca

View Study Details

NCT04775745Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell...

Durham, NCPHASE160 participantsNewave Pharmaceutical Inc

View Study Details

NCT05143996Recruiting

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)...

Durham, NCPHASE160 participantsCullinan Therapeutics Inc.

View Study Details

NCT05546580Recruiting

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat ...

Durham, NCPHASE150 participantsOryzon Genomics S.A.

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Durham, NCPHASE120 participantsAdaptimmune

View Study Details

NCT04704323Recruiting

CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e....

Durham, NCPHASE118 participantsCatapult Therapeutics

View Study Details

About Leukemia Clinical Trials in Durham

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 18 leukemia clinical trials recruiting participants in Durham, NC. These studies are seeking a combined 2,924 participants. Research is being sponsored by Revolution Medicines, Inc., Bristol-Myers Squibb, University of Kansas Medical Center and 12 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Durham — FAQ

Are there leukemia clinical trials in Durham?

Yes, there are 18 leukemia clinical trials currently recruiting in Durham, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Durham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you about next steps.

Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Durham studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 18 active trials in Durham are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 18, 2026 from ClinicalTrials.gov